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ABSTRACT 
 
Background: Increasingly, patients receiving methadone treatment are found in Low 
Threshold Facilities (LTF), which provide needle exchange programmes in Switzerland. 
This paper identifies the characteristics of LTF attendees receiving methadone treatment 
(MT) compared with other LTF attendees (non-MT). 
Methods: A national cross-sectional survey was conducted in 2006 over five 
consecutive days in all LTF (n=25). All attendees were given an anonymous 
questionnaire, including information on socio-demographic indicators, drug 
consumption, injection, methadone treatment, and self-reported HIV and HCV status. 
Univariate analysis and logistic regression were performed to compare MT to non-MT. 
Response rate was 66% (n=1128). 
Results: MT comprised 57.6% of the sample. In multivariate analysis, factors 
associated with being MT were older age (OR 1.38), female sex (OR: 1.60), having a 
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own accommodation (OR: 1.56), receiving public assistance (OR: 2.29), lifetime 
injecting (OR: 2.26), HIV-positive status (OR: 2.00), and having consumed cocaine 
during the past month (OR: 1.37); MT were less likely to have consumed heroin in the 
past month (OR: 0.76, not significant) and visited LTF less often on a daily basis (OR: 
0.59). The number of injections during the past week was not associated with MT. 
Conclusions: More LTF attendees were in the MT group, bringing to light an 
underappreciated LTF clientele with specific needs. The MT group consumption profile 
may reflect therapeutic failure or deficits in treatment quality. It is necessary to 
acknowledge this reality and to strengthen the awareness of LTF personnel about 
potential needs of MT attendees to meet their therapeutic goals. 
 
Key words:   
Low-threshold facilities, methadone, needle exchange programmes, Switzerland, harm 
reduction 
 
 
INTRODUCTION 
 
In Switzerland, Low-Threshold Facilities (LTF) with needle exchange programmes are 
at the front line of the harm reduction policy(Kübler & Wälti, 2001; Uchtenhagen, 
1995; Zobel et al., 2003). They mostly provide sterile injection/inhalation equipment, 
basic health care, sometimes counselling, but no substitution treatments(Benninghoff, 
1999). About half have a supervised drug consumption room (DCR) for injection or 
inhalation. LTF operate under the principle of anonymity, do not register clients; they 
may provide referrals but no follow-up. 
Methadone is widely prescribed to heroin users, only in medical settings. Most 
treatments are long term maintenance, and persistence of some consumption is generally 
not considered a reason to exclude patients(Swiss Society of Addiction Medicine, 
2010). About 2/3 of the 25,000 estimated heroin users are in treatment(Hosek, 2006; 
Maag, 2003; Schorr & Künzi, 2007). 
Previous studies, in Switzerland(Benninghoff, Morency, Geense, Huissoud, & Dubois-
Arber, 2006; Dubois-Arber et al., 2008) and elsewhere(Toufik, Cadet-Taïrou, Janssen, 
& Gandilhon, 2008; Valenciano, Emmanuelli, & Lert, 2001; E. Wood et al., 2005), have 
shown that a high proportion of LTF attendees - increasing in Switzerland - are 
currently on methadone treatment. Although this may not be surprising, it is not much 
recognized by LTF that do not have specific policies regarding these persons. Their 
characteristics are not well known, in particular, their consumption patterns and mode.  
The aims of this paper are to analyse the extent to which LTF users on methadone 
treatment (MT) are different from other LTF users (non-MT) in terms of socio-
demographic characteristics, drug use, health status, and social integration; and to 
discuss the implications of the findings for LTF management.  
 
METHODS 
 
A national cross-sectional survey among attendees of all LTF (n=25) in Switzerland 
was conducted in 2006(Balthasar et al., 2007). This survey, included in the national 
HIV surveillance system since 1993, monitors consumption patterns and preventive 
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behaviours in IDUs(Dubois-Arber, et al., 2008; Dubois-Arber, Jeannin, & Meystre-
Agustoni, 2006).  
During five consecutive days, all LTF attendees were invited to complete an anonymous 
questionnaire. The first part, related to consumption, was conducted face to face by 
trained interviewers; the second, including questions on health, was self-completed. The 
questionnaire included questions on: 
- Age, sex, education, income (not mutually exclusive: from a paid job, social 
insurance, public assistance, illegal activity), own accommodation. 
- Heroin and/or cocaine use in the past month, injection (never, ever and not previous 
week, previous week), and number of injections in previous week. 
- Perceived health; HIV, HCV testing (ever) and self-reported results, current 
substitution treatment. 
- Frequency of LTF visits (everyday, less often). 
Number and characteristics of non-participants (sex, estimated age, reason for refusal) 
were documented.  
The participation rate was 66.0% (n=1,128). Non-participants did not significantly 
differ from participants on sex and age. We excluded from the analysis the respondents: 
- -who had never consumed heroin nor cocaine (n=53); 
- -who did not answer the question on injection (n=5);  
- recruited from two LTF (n=54), with on site delivery of methadone treatment by a 
physician;  
To control potential bias, we also excluded respondents who had a substitution 
treatment other than methadone treatment (n=95). The final sample size under analysis 
was 921 respondents. 
Univariate analysis and logistic regression were performed to identify characteristics of 
patients in treatment (MT), versus non-treated (non-MT). Variables included were age 
in years and age squared, sex, heroin use (past month), cocaine use (past month), 
injection lifetime, number of injections (previous week), education, sources of income, 
own accommodation, perceived health status, self-reported HIV and HCV status, LTF 
attendance, recruitment in a LTF with an injection room (Table 1). 
Missing data (less than 3.0%), were excluded in the univariate analysis. The data were 
processed using SPSS software (version 15.0) for Windows (SPSS Inc., Chicago, 
Illinois 60606).  
 
RESULTS 
 
The average age of LTF attendees was 35.8 years. One fourth were women. 29.8% had 
completed only mandatory 9 years of schooling. 85.1% of participants lived in their 
own accommodation. 39.4% had a job in the past month, 43.2% reported an income 
from public assistance, one third (33.1%) from social insurance, and 21.2% from illicit 
activities.   
94.7% had ever used heroin, 71.9% had used heroin and 62.6% cocaine in the past 
month. 78.0% had ever injected drugs, 47.1% in the past week. HIV and HCV 
prevalence (among tested) were respectively 7.3% and 49.3%. 
57.6% of respondents were on methadone treatment. The average dosage was 72 
mg/day (median, 60 mg/day; range, 25 to 275 mg/day). The average treatment duration 
was 6.2 years (median, 4.2 years; range, 1 to 288 months). 
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INSERT TABLE 1 
 
MT were more likely to be female and supported by social insurance or public 
assistance, and less likely to have a paid job. They reported living in their own 
accommodation more often and used LTF less regularly than non-MT. 
MT were less likely to report heroin use in the past month (67.2% vs. 78.4%, p<0.001), 
but no significant difference was observed regarding cocaine use. Among non-MT, one 
third had never injected drugs in their lifetime compared with 14.6% among MT. 
Among those who had ever injected drugs in their lifetime, 57.0% (non-MT) and 62.4% 
(MT) had injected in the 7 last days (NS). 
More MT reported to have been tested for HIV and HCV (data not shown) and the 
related reported prevalences were significantly higher among MT. 
In logistic regression analysis (Table 1), the following variables were positively 
associated with the dependent variable (MT): older age, female sex, own 
accommodation in the past month, having a public assistance income, being HIV-
positive, having ever injected, and having used cocaine during the past month. MT also 
tended to be less likely to have used heroin (not significant), and were less likely to visit 
the LTF daily. No association was found with the frequency of injection in previous 
week.  
 
DISCUSSION 
 
The profile of MT attendees corresponds with ageing drug users with a long history of 
injection. They may be considered persons for whom methadone treatment is not fully 
effective (doses too low to suppress consumption) and/or inadequate (medical follow-up 
of insufficient quality not allowing to identify the persistence of consumption and 
injection). Although the average dose of methadone reported by MT is in line with the 
current Swiss recommendations (60–80 mg)(Swiss Society of Addiction Medicine, 
2010), the range is large. Regarding consumption, the profile of MT compared with 
non-MT is worrisome, having a higher proportion of cocaine users (probably replacing 
heroin in those who still need "shoots"), an absence of significant differences regarding 
the proportion of current heroine users, and no difference in the number of weekly 
injections. MT are also more likely to be HIV-positive. The picture emerging for MT in 
LTF is of a high risk population who would benefit from being identified as such and 
offered special attention to improve their treatment situation, including being offered 
supervised heroin treatment. Currently, this special attention is not offered in 
Switzerland and in some countries in Western Europe, who share the same LTF 
development(Hedrich, 2004).  
Switzerland was one of the first countries to develop LTF in the urgent context of an 
HIV/AIDS epidemic and open drug scenes, in the nineties. The role of LTF, when 
methadone treatment was not well developed, was to attract marginalised drug users and 
to be the first contact they had with health services. This required low threshold access, 
strong harm reduction orientation, anonymity (no registration, no history taking), no 
treatment requirement, no follow up. This harm reduction orientation in LTF was 
successful(Benninghoff, et al., 2006). Over the same period, methadone treatment was 
developed in parallel. However, harm reduction and treatment domains remained 
somewhat separated conceptually, with different professional identifications and tracks 
(mostly medical in treatment centres, predominantly socio-educational in LTF). The 
situation has evolved, since, and the overlap between these two "worlds" is significant, 
although insufficiently acknowledged in Switzerland. Generally, in the articles cited 
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above describing LTF clients(Toufik, et al., 2008; Valenciano, et al., 2001; E. Wood, et 
al., 2005), the high proportion of LTF users receiving methadone treatment is often 
mentioned, without further comment.  
Various studies showed that participation in a needle exchange programme may have a 
positive impact on the identification of health and social problems and referral to 
treatment programmes(Committee on the prevention of HIV infection among injecting 
drug users in high-risk countries, 2006; Hagan et al., 2000; Henderson, Vlahov, 
Celentano, & Strahtdee, 2003; Mac Master & Vail, 2002; Riley, Safaeian, Strathdee, 
Beilenson, & Vlahov, 2002). At population level, combination of LTF and adequate 
methadone treatment has been shown to contribute to decrease HIV and HCV 
transmission risk(van den Berg, Smit, van Brussel, Coutinho, & Prins, 2007). In 
countries where development of LTF is more recent, the objective of referring drug 
users to treatment is more prominent(E. Wood, Tyndall, Montaner, & Kerr, 2006). For 
example, in the context of the Vancouver DCR(E Wood et al., 2006), increased referral 
was noted when a social worker was actively working on this dimension. In 
Switzerland, however, LTF staff report not having enough time to discuss and orient 
drug users to other relevant health institutions(Spreyermann & Willen, 2003). 
Redefining the role and function of LTF for MT clients is needed. Their specific risks 
and needs should be better recognized. This implies reconsidering the issue of 
anonymity in LTF, and of the resources needed to be more proactive in identifying MT 
attendees and proposing a case management strategy in cooperation with treatment 
centres for those willing to do so. A specially trained professional (social worker, nurse) 
could initiate the collaboration with the medical doctor currently in charge of the 
treatment. Better identification of the treatment situation of LTF clients could improve 
treatment, including that of complex cases who often suffer from psychiatric problems. 
In the context of ageing cohorts of drug users, many of which receive long-term 
maintenance treatment, the sharp distinction between harm reduction centres and 
treatment centres should disappear.  
This study has limitations; non-respondents may differ from respondents on variables 
related to treatment or drug consumption; the methadone dose is the only proxy for 
treatment quality, and there was no specific assessment of mental condition that may be 
a confounder for (failed) treatment.  
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Table 1 Variables associated with being on methadone treatment (MT) 
 
  
n 
  
Univariate 
association 
(n=921)* 
      
Multivariate 
logistic 
regression 
(n=843)** 
   
    Factors MT 
non-
MT % OR 
95% 
IC      p=   OR 95% IC     p= 
                 Sex 
 
Male 374 309 54.8 1.00 
     
1.00 
    
  
Female 151 77 66.2 1.62 1.18 ; 2.21 0.01 
 
1.60 1.10 ; 2.32 0.01 
                 Age 
     
1.42 1.25 ; 1.62 <0.01 
 
1.38 1.19 ; 1.61 <0.01 
Age (squared) 
    
0.99 0.99 ; 1.00 <0.01 
 
1.00 0.99 ; 1.00 <0.01 
                 Education Mandatory school 149 121 55.2 1.00 
     
1.00 
    
  
Any higher degree 376 261 59.0 1.17 0.88 ; 1.56 0.28 
 
1.18 0.83 ; 1.68 0.37 
Income 
               
 
Paid job No 342 216 61.3 1.00 
     
1.00 
    
  
Yes 191 172 52.6 0.7 0.54 ; 0.91 0.01 
 
0.77 0.54 ; 1.11 0.16 
                 
 
Social insurance No 346 270 56.2 1.00 
     
1.00 
    
  
Yes 187 118 61.3 1.24 0.93 ; 1.64 0.14 
 
1.12 0.75 ; 1.66 0.54 
                 
 
Public assistance No 272 251 52.0 1.00 
     
1.00 
    
  
Yes 261 137 65.6 1.76 1.34 ; 2.31 <0.01 
 
2.29 1.57 ; 3.32 <0.01 
                 
 
Illegal activity No 436 290 60.1 1.00 
     
1.00 
    
  
Yes 97 98 49.7 0.66 0.48 ; 0.91 0.01 
 
0.72 0.49 ; 1.06 0.09 
                 Own accommodation (past month) No 69 68 50.4 1.00 
     
1.00 
    
  
Yes 464 320 59.2 1.43 0.99 ; 2.06 0.05 
 
1.56 1.00 ; 2.44 0.05 
                 Perceived health status Good, rather good 369 270 57.7 1.00 
     
1.00 
    
  
Bad, rather bad 144 93 60.8 1.13 0.84 ; 1.54 0.42 
 
1.14 0.81 ; 1.62 0.75 
                 Injection lifetime No 78 125 38.4 1.00 
     
1.00 
    
  
Yes 455 263 63.4 2.77 2.00 ; 3.85 <0.01 
 
2.26 1.52 ; 3.36 <0.01 
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                 Number of injections last week 
    
1.02 0.99 ; 1.04 0.11 
 
0.99 0.98 ; 1.00 0.07 
                 Heroin use (past month) No 173 83 67.6 1.00 
     
1.00 
    
  
Yes 355 301 54.1 0.57 0.42 ; 0.77 <0.01 
 
0.76 0.53 ; 1.08 0.13 
                 Cocain use (past month) No 187 154 54.8 1.00 
     
1.00 
    
  
Yes 340 231 59.5 1.21 0.92 ; 1.59 0.16 
 
1.37 1.00 ; 1.89 0.05 
                 HIV status (reported) Seronegative 481 373 56.3 1.00 
     
1.00 
    
  
Seropositive 52 15 77.6 2.69 1.48 ; 4.87 <0.01 
 
2.00 1.02 ; 3.91 0.04 
                 HCV status (reported) Seronegative 290 272 51.6 1.00 
     
1.00 
    
  
Seropositive 243 116 67.7 1.96 1.49 ; 2.60 <0.01 
 
1.13 0.80 ; 1.61 0.49 
                 Recruited in LTF with No 151 119 55.9 1.00 
     
1.00 
    
 
injection room Yes 382 269 58.7 1.12 0.84 ; 1.49 0.44 
 
1.24 0.88 ; 1.76 0.22 
                 Frequency of LTF visit less than everyday 385 230 62.6 1.00 
     
1.00 
        everyday 141 155 47.6 0.54 0.41 ; 0.72 <0.01   0.59 0.42 ; 0.84 <0.01 
                 * Number of participants may differ in univariate analysis due to excluded missing data 
          ** Participants with full information were included in the multivariate logistic regression 
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